Glytec announced today that it expanded its collaboration with Roche to integrate software with smart diabetes technology.
The two companies initially struck a partnership in early 2022. They aimed to combine Glytec’s FDA-cleared Glucommander insulin dosing decision support software with Roche’s expertise in medical devices and IT solutions. It marked an effort to address the challenges associated with inpatient blood sugar management at the hospital bedside.
With the collaboration, Glucommander became the first software application available on Roche’s Cobas Pulse smart-device, next-generation hospital blood glucose system.
Today’s expansion allows for the use of Glytec software with Cobas Pulse in the U.S. and other worldwide markets where both have availability.
Roche — one of the world’s largest diabetes technology companies — developed Cobas Pulse to improve patient safety and care. The platform enables point-of-care clinicians to collect and take immediate action on glycemic management data. Combining hardware and software brings together the immediacy of a bedside blood glucose test with Glytec’s insulin decision support on a single, handheld device to streamline workflows and save time.
“Diabetes knows no borders, profoundly impacting hospital diabetes management and patient outcomes worldwide. We are proud of our expanded collaboration with Roche, which reaffirms our commitment to addressing this critical healthcare challenge for patients, providers, and payors and positively impacting lives worldwide,” said Robby Booth, co-founder and chief strategy officer at Glytec.
